Centogene N.V. (CNTG) | Investment Case

1. Company Snapshot

1.a. Company Description

Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide.It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing.The company develops rare disease platform, a data and biological repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs.

It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors.The company also offers COVID-19 testing solutions, including PCR and antigen testing services.It has collaboration and license agreements with Shire International GmbH, Pfizer Inc., Dr. Bauer Laboratoriums GmbH, Fraport AG, Takeda Pharmaceutical Company Limited, and Twist Bioscience Corporation.

Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.

Show Full description

1.b. Last Insights on CNTG

CENTOGENE N.V. recently announced the approval of all resolutions, including the announced transaction with Charme Capital Partners, at its Extraordinary General Meeting. This development is a positive driver, as it provides a stable financial foundation for the company's future growth. Additionally, the company's recent focus on expanding its presence in the genetic testing market through strategic partnerships and acquisitions is expected to drive revenue growth. The company's increasing demand for its non-invasive genetic testing solutions is also a key driver, as it offers a more convenient and cost-effective alternative to traditional testing methods."

1.c. Company Highlights

Last Price	0.33
Change Percentage	100.00%
Open	0.33
Previous Close	0.33
Market Cap ( Millions)	9
Volume	7229138
Year High	0.43
Year Low	0.33
M A 50	0.16
M A 200	0.26

FCF Yield	-420.60%
Dividend Yield	0.00%
ROE	397.65%
Debt / Equity	-318.03%
Net Debt / EBIDTA	-320.22%
Price To Book	-0.31
Price Earnings Ratio	-0.22
Price To FCF	-0.24
Price To sales	0.17
EV / EBITDA	-3.62

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

CENTOGENE Closes Strategic Transaction with Private Equity Group Charme Capital Partners

Mar -12

Source: globenewswire.com

CENTOGENE Announces Voting Results of Extraordinary General Meeting

Dec -05

Source: globenewswire.com

CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners

Nov -13

Source: globenewswire.com

CENTOGENE Data on Novel Genetic Risk Factor for Parkinson's Disease in The Lancet Neurology

Sep -25

Source: globenewswire.com

CENTOGENE Receives Delisting Notice From Nasdaq

Aug -07

Source: globenewswire.com

CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson's Disease Cases Are Linked to Genetic Factors

Aug -01

Source: globenewswire.com

C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development

Jun -20

Source: globenewswire.com

CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting

May -31

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.43%)

6. Segments

Diagnostics

Expected Growth: 10.43%

Centogene N.V.'s diagnostics segment growth of 10.43% is driven by increasing demand for genetic testing, expansion into new markets, and strategic partnerships. The company's focus on rare genetic disorders and its proprietary CE-marked tests also contribute to growth. Additionally, investments in digital health and AI-powered diagnostics enhance the company's offerings, attracting more customers and driving revenue growth.

Pharmaceutical

Expected Growth: 10.43%

Centogene N.V.'s 10.43% growth in pharmaceuticals is driven by increasing demand for genetic diagnostics, expansion into new markets, and strategic partnerships. The company's unique genetic testing capabilities and growing database of genetic information also contribute to its growth. Additionally, the rising prevalence of genetic disorders and increasing adoption of precision medicine further fuel the segment's growth.

7. Detailed Products

CentoMD

CentoMD is a genetic diagnostic platform that provides a comprehensive genetic diagnosis for patients with rare genetic disorders.

CentoXome

CentoXome is a whole-exome sequencing test that analyzes a patient's entire protein-coding genome to identify genetic variations associated with rare diseases.

CentoArray

CentoArray is a genetic testing platform that uses microarray technology to detect chromosomal abnormalities and genetic variations associated with rare diseases.

CentoGenome

CentoGenome is a whole-genome sequencing test that analyzes a patient's entire genome to identify genetic variations associated with rare diseases.

CentoMetabolic

CentoMetabolic is a genetic testing platform that analyzes genes associated with inborn errors of metabolism, enabling early diagnosis and treatment of metabolic disorders.

CentoCardio

CentoCardio is a genetic testing platform that analyzes genes associated with cardiovascular disease, enabling early diagnosis and prevention of cardiovascular events.

8. Centogene N.V.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Centogene N.V. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the emergence of new technologies and competitors.

Bargaining Power Of Customers

Centogene N.V. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's unique offerings and expertise in rare genetic disorders give it a competitive advantage.

Bargaining Power Of Suppliers

Centogene N.V. relies on a few key suppliers for its operations, which gives them some bargaining power. However, the company's strong relationships with its suppliers and its ability to negotiate contracts mitigate this risk.

Threat Of New Entrants

The genetic testing and diagnostics market has high barriers to entry, including significant capital requirements, regulatory hurdles, and the need for specialized expertise. This limits the threat of new entrants.

Intensity Of Rivalry

The genetic testing and diagnostics market is highly competitive, with several established players competing for market share. Centogene N.V. must continually innovate and differentiate itself to maintain its competitive edge.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	159.27%
Debt Cost	3.95%
Equity Weight	-59.27%
Equity Cost	0.60%
WACC	5.93%
Leverage	-268.73%

11. Quality Control: Centogene N.V. passed 3 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Clínica Baviera

A-Score: 6.9/10

Value: 4.1

Growth: 8.2

Quality: 8.4

Yield: 7.5

Momentum: 7.0

Volatility: 6.3

1-Year Total Return ->

Voxel

A-Score: 6.7/10

Value: 3.6

Growth: 7.7

Quality: 6.9

Yield: 6.9

Momentum: 9.5

Volatility: 5.3

1-Year Total Return ->

Lumibird

A-Score: 3.7/10

Value: 2.3

Growth: 5.4

Quality: 3.2

Yield: 0.0

Momentum: 10.0

Volatility: 1.0

1-Year Total Return ->

Centogene

A-Score: 3.5/10

Value: 10.0

Growth: 1.4

Quality: 5.5

Yield: 0.0

Momentum: 4.0

Volatility: 0.0

1-Year Total Return ->

Vimian Group

A-Score: 2.9/10

Value: 2.1

Growth: 7.2

Quality: 5.5

Yield: 0.0

Momentum: 1.0

Volatility: 1.7

1-Year Total Return ->

Selvita

A-Score: 2.3/10

Value: 3.5

Growth: 4.9

Quality: 3.7

Yield: 0.0

Momentum: 0.0

Volatility: 2.0

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

12.74%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

5.93%

Centogene N.V. - NL0014040206

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on CNTG

1.c. Company Highlights

Cheaper

Lower Growth

More Volatile

Earnings Miss

Revenues Miss

Earnings Beats

Revenues Beats

Medium Volatility

Average Yield

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.43%)

6. Segments

Diagnostics

Expected Growth: 10.43%

Pharmaceutical

Expected Growth: 10.43%

7. Detailed Products

CentoMD

CentoXome

CentoArray

CentoGenome

CentoMetabolic

CentoCardio

8. Centogene N.V.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Centogene N.V. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

0.32$

Current Price

0.33$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA